Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transthoracic echocardiography-the overlooked sentinel for pseudoaneurysm: a case report.

European heart journal. Case reports·2026

Same author

Cardiac amyloidosis with apical myocardial infarction: beyond the cherry on top.

ESC heart failure·2026

Same author

Healthcare professionals' perspectives on the barriers and enablers of cancer clinical trial participation among Arabic-speaking cancer patients in Australia: a qualitative study.

Trials·2026

Same author

Label-free optical observation of disordered-to-ordered transitions in single intrinsically disordered proteins.

Npj biosensing·2026

Same author

A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026

Same author

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use.

Journal for immunotherapy of cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Cetuximab-associated pulmonary toxicity.

Wei Chua¹, Matthew Peters, Robert Loneragan

¹Department of Medical Oncology, Concord Repatriation General Hospital, Concord, NSW, Australia. weic@med.usyd.edu.au

Clinical Colorectal Cancer

|September 10, 2009

Summary

This summary is machine-generated.

Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, can cause rare lung toxicity like bronchiolitis obliterans organizing pneumonia in colorectal cancer patients. This case highlights the importance of considering drug-induced pulmonary toxicity.

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jun 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Area of Science:

Oncology
Pulmonology
Pharmacology

Background:

Epidermal growth factor receptor (EGFR) inhibitors are increasingly used for head and neck, non-small-cell lung, and colorectal cancers.
Cetuximab is an EGFR inhibitor used in treating metastatic colorectal cancer (CRC).

Observation:

A 78-year-old man with metastatic CRC received cetuximab plus irinotecan as third-line therapy.
Two months post-treatment, the patient developed symptoms of bronchiolitis obliterans organizing pneumonia.

Findings:

The patient's pulmonary condition was deemed secondary to cetuximab treatment.
Pulmonary toxicity associated with cetuximab is rare, unlike the more common interstitial fibrosis seen with other EGFR inhibitors (gefitinib, erlotinib).

Implications:

This case underscores the need to consider drug-induced pulmonary toxicity in patients with advanced CRC presenting with pulmonary infiltrates.
Early recognition and diagnosis of drug-related lung injury are crucial for patient management and outcomes.